Chugai, Eisai, SoftBank, Takeda and Celgene have contributed to healthcare venture firm Catalys Pacific’s inaugural fund, which has a target size of $100m.

Japan-based venture capital firm Catalys Pacific officially launched a $100m healthcare fund on Monday backed by life sciences companies Celgene, Chugai Pharmaceutical, Eisai and Takeda Pharmaceutical. Internet and telecommunications conglomerate SoftBank has also provided capital for the fund. Catalys has not confirmed whether it has reached the $100m target, indicated in a regulatory filing in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.